Germany · Delayed Price · Currency is EUR Epigenomics AG Statistics
Total Valuation
Epigenomics AG has a market cap or net worth of EUR 789,278. The enterprise value is 11.89 million.
| Market Cap | 789,278 |
| Enterprise Value | 11.89M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Epigenomics AG has 876,976 shares outstanding. The number of shares has increased by 0.00% in one year.
| Current Share Class | 876,976 |
| Shares Outstanding | 876,976 |
| Shares Change (YoY) | +0.00% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | 622,111 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.31 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 58.60
| Current Ratio | 58.60 |
| Quick Ratio | 55.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1.68% |
| Return on Invested Capital (ROIC) | -1.73% |
| Return on Capital Employed (ROCE) | -2.72% |
| Weighted Average Cost of Capital (WACC) | 0.59% |
| Revenue Per Employee | 15,000 |
| Profits Per Employee | -119,000 |
| Employee Count | 3 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.88% in the last 52 weeks. The beta is 0.87, so Epigenomics AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | +5.88% |
| 50-Day Moving Average | 0.93 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 45.55 |
| Average Volume (20 Days) | 161 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Epigenomics AG had revenue of EUR 30,000 and -238,000 in losses. Loss per share was -0.27.
| Revenue | 30,000 |
| Gross Profit | 30,000 |
| Operating Income | -315,000 |
| Pretax Income | -238,000 |
| Net Income | -238,000 |
| EBITDA | n/a |
| EBIT | -315,000 |
| Loss Per Share | -0.27 |
Balance Sheet
The company has 277,000 in cash and 11.38 million in debt, with a net cash position of -11.10 million or -12.66 per share.
| Cash & Cash Equivalents | 277,000 |
| Total Debt | 11.38M |
| Net Cash | -11.10M |
| Net Cash Per Share | -12.66 |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | 288,000 |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,050.00% |
| Pretax Margin | -793.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Epigenomics AG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.00% |
| Shareholder Yield | -0.00% |
| Earnings Yield | -30.15% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 8, 2023. It was a reverse split with a ratio of 0.2.
| Last Split Date | Dec 8, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
Epigenomics AG has an Altman Z-Score of -10.79 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.79 |
| Piotroski F-Score | 3 |